| __timestamp | Geron Corporation | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20707000 | 19586000 |
| Thursday, January 1, 2015 | 17831000 | 29135000 |
| Friday, January 1, 2016 | 18047000 | 42791000 |
| Sunday, January 1, 2017 | 11033000 | 49577000 |
| Monday, January 1, 2018 | 13432000 | 89209000 |
| Tuesday, January 1, 2019 | 52072000 | 69099000 |
| Wednesday, January 1, 2020 | 51488000 | 75961000 |
| Friday, January 1, 2021 | 85727000 | 90467000 |
| Saturday, January 1, 2022 | 95518000 | 74552000 |
| Sunday, January 1, 2023 | 125046000 | 91593000 |
In pursuit of knowledge
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Supernus Pharmaceuticals, Inc. and Geron Corporation have demonstrated distinct strategies in their R&D allocations. From 2014 to 2023, Supernus Pharmaceuticals increased its R&D expenses by approximately 368%, peaking in 2023. This reflects a robust commitment to advancing their pipeline and expanding their therapeutic offerings. Meanwhile, Geron Corporation's R&D spending surged by over 500% during the same period, highlighting their aggressive pursuit of novel treatments in oncology. Notably, in 2023, Geron's R&D expenses surpassed Supernus by about 36%, indicating a strategic pivot towards intensive research efforts. These trends underscore the dynamic nature of R&D investments in the biopharmaceutical sector, where companies continuously adapt to scientific advancements and market demands.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Supernus Pharmaceuticals, Inc.
R&D Insights: How Sanofi and Geron Corporation Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
R&D Insights: How Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation
Analyzing R&D Budgets: Supernus Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.